Raymond E. Felgar

3.7k total citations · 1 hit paper
38 papers, 2.8k citations indexed

About

Raymond E. Felgar is a scholar working on Pathology and Forensic Medicine, Immunology and Genetics. According to data from OpenAlex, Raymond E. Felgar has authored 38 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 16 papers in Immunology and 10 papers in Genetics. Recurrent topics in Raymond E. Felgar's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Immune Cell Function and Interaction (9 papers). Raymond E. Felgar is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Immune Cell Function and Interaction (9 papers). Raymond E. Felgar collaborates with scholars based in United States, Spain and Poland. Raymond E. Felgar's co-authors include Jennifer H. Anolik, Iñaki Sanz, Faith Young, Joseph D. Rosenblatt, Debbie Campbell, R. John Looney, James A. Sloand, R. John Looney, Lois J. Arend and Kevin E. Salhany and has published in prestigious journals such as Blood, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Raymond E. Felgar

38 papers receiving 2.7k citations

Hit Papers

B cell depletion as a nov... 2004 2026 2011 2018 2004 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
    2004 616 citations R. John Looney, Jennifer H. Anolik et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raymond E. Felgar United States 22 1.4k 891 813 682 536 38 2.8k
Ingrid Simonitsch‐Klupp Austria 29 816 0.6× 1.1k 1.2× 374 0.5× 270 0.4× 376 0.7× 93 2.4k
Edward M Vital United Kingdom 34 2.0k 1.4× 567 0.6× 2.6k 3.1× 995 1.5× 434 0.8× 147 3.9k
Yoshitoyo Kagami Japan 35 1.0k 0.8× 2.3k 2.5× 409 0.5× 173 0.3× 705 1.3× 102 3.9k
James N. Gilliam United States 28 1.2k 0.9× 912 1.0× 1.8k 2.2× 780 1.1× 209 0.4× 56 2.8k
Jörn Drappa United States 21 2.1k 1.6× 358 0.4× 1.6k 2.0× 667 1.0× 153 0.3× 31 3.3k
Junichi Kaburaki Japan 29 876 0.6× 1.2k 1.4× 799 1.0× 289 0.4× 121 0.2× 69 2.6k
Kyriakos A. Kirou United States 34 2.9k 2.2× 526 0.6× 2.6k 3.2× 640 0.9× 114 0.2× 73 4.3k
Piersandro Riboldi Italy 20 546 0.4× 522 0.6× 1.0k 1.2× 152 0.2× 430 0.8× 50 1.5k
Bernard Lauwerys Belgium 29 1.3k 0.9× 248 0.3× 1.4k 1.8× 317 0.5× 127 0.2× 84 2.5k
Marie‐Christine Jacob France 21 563 0.4× 331 0.4× 272 0.3× 181 0.3× 240 0.4× 66 1.4k

Countries citing papers authored by Raymond E. Felgar

Since Specialization
Citations

This map shows the geographic impact of Raymond E. Felgar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond E. Felgar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond E. Felgar more than expected).

Fields of papers citing papers by Raymond E. Felgar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond E. Felgar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond E. Felgar. The network helps show where Raymond E. Felgar may publish in the future.

Co-authorship network of co-authors of Raymond E. Felgar

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond E. Felgar. A scholar is included among the top collaborators of Raymond E. Felgar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond E. Felgar. Raymond E. Felgar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monaghan, Sara A., Raymond E. Felgar, Melissa Kelly, et al.. (2016). Does Taking the Fellowship In-Service Hematopathology Examination and Performance Relate to Success on the American Board of Pathology Hematology Examination?. American Journal of Clinical Pathology. 146(1). 107–112. 6 indexed citations
2.
Wilson, Amanda L., Steven H. Swerdlow, Grzegorz K. Przybylski, et al.. (2013). Intestinal γδ T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. Human Pathology. 44(6). 1131–1145. 16 indexed citations
3.
Lieberman, Frank S., Victor Yazbeck, Anastasios Raptis, Raymond E. Felgar, & Michael Boyiadzis. (2011). Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. Journal of Neuro-Oncology. 107(2). 225–232. 22 indexed citations
4.
5.
Monaco, Sara E., Lisa A. Teot, Raymond E. Felgar, Urvashi Surti, & Guoping Cai. (2009). Fluorescence in situ hybridization studies on direct smears. Cancer Cytopathology. 117(5). 338–348. 28 indexed citations
6.
Dufresne, Scott D., Raymond E. Felgar, Rachel L. Sargent, et al.. (2009). Defining the borders of splenic marginal zone lymphoma: a multiparameter study. Human Pathology. 41(4). 540–551. 18 indexed citations
7.
Vargas, Roberto L., Raymond E. Felgar, & Paul G. Rothberg. (2007). Detection of clonality in lymphoproliferations using PCR of the antigen receptor genes: Does size matter?. Leukemia Research. 32(2). 335–338. 14 indexed citations
8.
9.
Ryan, Elizabeth P., et al.. (2005). Activated Human B Lymphocytes Express Cyclooxygenase-2 and Cyclooxygenase Inhibitors Attenuate Antibody Production. The Journal of Immunology. 174(5). 2619–2626. 82 indexed citations
10.
Ryan, Elizabeth P., et al.. (2005). Activated Human B Lymphocytes Express Cyclooxygenase-2 and Cyclooxygenase Inhibitors Attenuate Ab Production. The Journal of Immunology. 174(8). 5134–5134. 1 indexed citations
11.
Zand, Martin S., Raymond E. Felgar, Jane L. Liesveld, et al.. (2005). Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 107(7). 2895–2903. 68 indexed citations
12.
Anolik, Jennifer H., Jennifer Barnard, Amedeo Cappione, et al.. (2004). Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis & Rheumatism. 50(11). 3580–3590. 360 indexed citations
13.
Looney, R. John, Jennifer H. Anolik, Debbie Campbell, et al.. (2004). B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab. Arthritis & Rheumatism. 50(8). 2580–2589. 616 indexed citations breakdown →
14.
Segel, George B., Timothy J. Woodlock, Jia Xu, et al.. (2003). Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype. Blood Cells Molecules and Diseases. 30(3). 277–287. 8 indexed citations
15.
Horan, John, et al.. (2003). A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research. 28. 65–69. 18 indexed citations
16.
Anolik, Jennifer H., Debbie Campbell, Raymond E. Felgar, et al.. (2003). The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis & Rheumatism. 48(2). 455–459. 358 indexed citations
17.
Komrokji, Rami S., Jeffrey E. Lancet, Raymond E. Felgar, Nancy Wang, & John M. Bennett. (2003). Burkitt’s leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt’s leukemia/lymphoma): case report and review of literature. Leukemia Research. 27(6). 561–566. 20 indexed citations
18.
Przybylski, Grzegorz K., Hong Wu, William R. Macon, et al.. (2000). Hepatosplenic and Subcutaneous Panniculitis-Like γ/δ T Cell Lymphomas Are Derived from Different Vδ Subsets of γ/δ T Lymphocytes. Journal of Molecular Diagnostics. 2(1). 11–19. 72 indexed citations
19.
Felgar, Raymond E. & John C. Hiserodt. (1990). In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cellular Immunology. 129(2). 288–298. 29 indexed citations
20.
Coss, Ronald A., et al.. (1989). Effects of verapamil and diltiazem on hyperthermic cell death in CHO cells. International Journal of Hyperthermia. 5(3). 383–387. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingrid Simonitsch‐Klupp Breakdown of academic impact, for papers by Edward M Vital Breakdown of academic impact, for papers by Yoshitoyo Kagami Breakdown of academic impact, for papers by James N. Gilliam Breakdown of academic impact, for papers by Jörn Drappa Breakdown of academic impact, for papers by Junichi Kaburaki Breakdown of academic impact, for papers by Kyriakos A. Kirou Breakdown of academic impact, for papers by Piersandro Riboldi Breakdown of academic impact, for papers by Bernard Lauwerys Breakdown of academic impact, for papers by Marie‐Christine Jacob
Rankless by CCL
2026